Korean brain-imaging AI company Neurophet has brought in former RadNet technology chief Lawrence N. Tanenbaum to advise the U.S. push for its FDA-cleared Alzheimer’s imaging software, a product aimed at MRI and PET monitoring as new dementia drugs reshape clinical demand.
Neurophet said Thursday that Tanenbaum, a U.S. neuroradiologist with more than 30 years of experience in medical imaging, has joined its scientific advisory board.
“I deeply share Neurophet’s technology and vision,” Tanenbaum said in the company’s announcement. “I will actively contribute so that AI-based medical imaging technology can create greater value in real-world clinical practice.”
Lawrence N. Tanenbaum, former RadNet technology chief, has joined Neurophet’s scientific advisory board as the company targets the U.S. Alzheimer’s imaging market. (Courtesy of Neurophet.)
The company won U.S. FDA 510(k) clearance in late January for Neurophet AQUA AD Plus, its brain imaging software for Alzheimer’s treatment-related decisions.
Neurophet told Korea Biomedical Review that Tanenbaum was appointed April 1 and will advise mainly on AQUA AD Plus, while also supporting the clinical use and market competitiveness of other key products.
The company said his role will include overseas commercialization, using his academic and clinical network in North America.
Tanenbaum previously served as vice president and chief technology officer at RadNet, which says it operates 435 outpatient imaging centers across the U.S. RadNet hired him in 2015 to work across CT, MRI and advanced imaging, including protocols, workflow and clinical operations.
His recent work has tracked closely with the market Neurophet is trying to enter.
Tanenbaum has previously backed AI tools for Alzheimer’s imaging, saying in a Darmiyan
announcement
that the company’s BrainSee software could “unlock value” from brain MRI by giving doctors objective measures for prognosis, monitoring and precision medicine.
Tanenbaum has
warned
that anti-amyloid Alzheimer’s drugs would drive a “substantial uptick” in brain MRI scans and give AI a role in screening for ARIA, which can appear as brain swelling, microbleeds or superficial siderosis.
That monitoring burden now sits at the center of treatment with drugs such as Eisai and Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab), whose labels require baseline and follow-up MRIs.
AQUA AD Plus is built for that setting. FDA documents say the software analyzes MRI and PET scans, measuring brain structures and lesions, comparing brain volume data with reference data and quantifying PET imaging values.
Neurophet has been seeking to position the product within the U.S. Alzheimer’s treatment system.
In March, the company signed a memorandum of understanding (MOU) with ALZ-NET, a U.S. Alzheimer’s treatment and diagnostics network, to support imaging monitoring for Alzheimer’s therapies and raise awareness of ARIA monitoring.
Kim Ji-hye
댓글
0